A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic.

MLA

Reynales, Humberto, et al. “A Prospective Observational Safety Study on MF59(®) Adjuvanted Cell Culture-Derived Vaccine, Celtura(®) during the A/H1N1 (2009) Influenza Pandemic.” Vaccine, vol. 30, no. 45, Oct. 2012, pp. 6436–43. EBSCOhost, https://doi.org/10.1016/j.vaccine.2012.08.005.

APA

Reynales, H., Astudillo, P., de Vallière, S., Hatz, C., Schlagenhauf, P., Rath, B., Velentgas, P., Fariña, A., Sales-Carmona, V., & Groth, N. (2012). A prospective observational safety study on MF59(®) adjuvanted cell culture-derived vaccine, Celtura(®) during the A/H1N1 (2009) influenza pandemic. Vaccine, 30(45), 6436–6443. https://doi.org/10.1016/j.vaccine.2012.08.005

Chicago

Reynales, Humberto, Pedro Astudillo, Serge de Vallière, Christoph Hatz, Patricia Schlagenhauf, Barbara Rath, Priscilla Velentgas, Ariel Fariña, Victor Sales-Carmona, and Nicola Groth. 2012. “A Prospective Observational Safety Study on MF59(®) Adjuvanted Cell Culture-Derived Vaccine, Celtura(®) during the A/H1N1 (2009) Influenza Pandemic.” Vaccine 30 (45): 6436–43. doi:10.1016/j.vaccine.2012.08.005.